Abstract
The anticonvulsant properties of sodium valproate (Epilim) were first recognised in 1963 and it has subsequently been shown to be effective for the treatment of many forms of epilepsy. The pharmacokinetics of valproic acid have been examined but only limited information is available on the degree and nature of its binding by protein. The authors report the results of an in vitro examination of the binding of valproic acid by human serum proteins and the interaction with some other drugs.